{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:52:48Z","timestamp":1791010368988,"version":"4.1.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The introduction of anti-amyloid-\u03b2 antibody therapies has fundamentally changed the clinical landscape of dementia, shifting the role of neuroimaging from diagnosis toward therapeutic decision-making. Amyloid positron emission tomography (PET) has become essential for confirming amyloid pathology and determining treatment eligibility. However, amyloid deposition is frequently observed in cognitively normal elderly individuals and in non-Alzheimer neurodegenerative disorders, indicating that amyloid status alone is insufficient to explain clinical symptoms. In this context, imaging modalities reflecting neurodegeneration, including structural magnetic resonance imaging (MRI) and functional imaging such as\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG-PET and brain perfusion single-photon emission computed tomography (SPECT), remain important for assessing disease severity and functional impairment. Furthermore, discrepancies between imaging biomarkers\u2014such as the presence of neurodegeneration without amyloid pathology in cases clinically suspected of Alzheimer\u2019s disease, and atypical imaging patterns\u2014are commonly encountered in clinical practice and may reflect underlying pathological heterogeneity. A multimodal imaging approach that integrates multiple biomarkers provides complementary information and may improve diagnostic accuracy and clinical interpretation. In addition, other imaging modalities, including dopamine transporter (DAT) imaging and cardiac sympathetic imaging, can contribute to the evaluation of non-Alzheimer pathologies. This review summarizes the current roles of clinically available multimodal imaging in dementia, with a focus on nuclear medicine and MRI, highlighting their complementary value and clinical implications in the era of disease-modifying therapies.\n                  <\/jats:p>","DOI":"10.1007\/s11604-026-02080-9","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:43:32Z","timestamp":1791002612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multimodal neuroimaging in dementia and neurodegenerative disorders: complementary roles of clinically available nuclear medicine and MRI in the era of disease-modifying therapies"],"prefix":"10.1007","author":[{"given":"Yoshitaka","family":"Inui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Takechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"2080_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"2080_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"key":"2080_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306\u201319.","journal-title":"Ann Neurol"},{"key":"2080_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275\u201383.","journal-title":"JAMA"},{"key":"2080_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287\u201394.","journal-title":"JAMA Neurol"},{"key":"2080_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s11604-026-01998-4","author":"K Ishii","year":"2026","unstructured":"Ishii K. Brain PET in the era of anti-amyloid-\u03b2 antibody therapy for Alzheimer disease. Jpn J Radiol. 2026. https:\/\/doi.org\/10.1007\/s11604-026-01998-4.","journal-title":"Jpn J Radiol"},{"key":"2080_CR7","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2015.4669","volume":"313","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313:1939\u201349.","journal-title":"JAMA"},{"key":"2080_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"2080_CR9","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20:5143\u201369.","journal-title":"Alzheimers Dement"},{"key":"2080_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","volume":"71","author":"TG Beach","year":"2005","unstructured":"Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005\u20132010. J Neuropathol Exp Neurol. 2005;71:266\u201373.","journal-title":"J Neuropathol Exp Neurol"},{"key":"2080_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/jnen\/nlaa014","volume":"79","author":"K Gauthreaux","year":"2020","unstructured":"Gauthreaux K, Bonnett TA, Besser LM, Brenowitz WD, Teylan M, Mock C, et al. Concordance of clinical Alzheimer diagnosis and neuropathological features at autopsy. J Neuropathol Exp Neurol. 2020;79:465\u201373.","journal-title":"J Neuropathol Exp Neurol"},{"key":"2080_CR12","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","volume":"69","author":"JA Schneider","year":"2007","unstructured":"Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197\u2013204.","journal-title":"Neurology"},{"key":"2080_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-014-0082-1","volume":"6","author":"J Rahimi","year":"2014","unstructured":"Rahimi J, Kovacs GG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther. 2014;6:82.","journal-title":"Alzheimers Res Ther"},{"key":"2080_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nrneurol.2015.251","volume":"12","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, Knopman DS, Ch\u00e9telat G, Dickson D, Fagan AM, Frisoni GB, et al. Suspected non-Alzheimer disease pathophysiology\u2013-concept and controversy. Nat Rev Neurol. 2016;12:117\u201324.","journal-title":"Nat Rev Neurol"},{"key":"2080_CR15","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 2015;11:964\u201374.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"2080_CR16","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s11604-025-01773-x","volume":"43","author":"S Kakeda","year":"2025","unstructured":"Kakeda S, Miki Y, Kudo K, Mori H, Tokumaru AM, Abe O, et al. Practical brain MRI guidelines for anti-A\u03b2 antibody treatment in early symptomatic Alzheimer\u2019s disease. Jpn J Radiol. 2025;43(8):1231\u20138.","journal-title":"Jpn J Radiol"},{"key":"2080_CR17","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/jnnp-2017-316851","volume":"89","author":"A Charidimou","year":"2018","unstructured":"Charidimou A, Farid K, Tsai HH, Tsai LK, Yen RF, Baron JC. Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance. J Neurol Neurosurg Psychiatry. 2018;89:410\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2080_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 2010;9(1):119\u201328.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2080_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207\u201316.","journal-title":"Lancet Neurol"},{"key":"2080_CR20","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/archneurol.2009.279","volume":"66","author":"NJ Cairns","year":"2009","unstructured":"Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 2009;66:1557\u201362.","journal-title":"Arch Neurol"},{"issue":"Suppl 2","key":"2080_CR21","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.2967\/jnumed.124.268756","volume":"66","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. J Nucl Med. 2025;66(Suppl 2):S5\u201331.","journal-title":"J Nucl Med"},{"key":"2080_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2967\/jnumed.124.268119","volume":"66","author":"LE Collij","year":"2025","unstructured":"Collij LE, Bischof GN, Altomare D, Bader I, Battle M, V\u00e1llez Garc\u00eda D, et al. Quantification supports amyloid PET visual assessment of challenging cases: results from the AMYPAD Diagnostic and Patient Management Study. J Nucl Med. 2025;66:110\u20136.","journal-title":"J Nucl Med"},{"key":"2080_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1-15.e4.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"2080_CR24","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s12149-024-01919-3","volume":"38","author":"C Shang","year":"2024","unstructured":"Shang C, Sakurai K, Nihashi T, Arahata Y, Takeda A, Ishii K, et al. Comparison of consistency in centiloid scale among different analytical methods in amyloid PET: the CapAIBL, VIZCalc, and Amyquant methods. Ann Nucl Med. 2024;38(6):460\u20137.","journal-title":"Ann Nucl Med"},{"key":"2080_CR25","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1002\/alz.13761","volume":"20","author":"A Bollack","year":"2024","unstructured":"Bollack A, Collij LE, Garc\u00eda DV, Shekari M, Altomare D, Payoux P, et al. Investigating reliable amyloid accumulation in Centiloids: results from the AMYPAD Prognostic and Natural History Study. Alzheimers Dement. 2024;20:3429\u201341.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"2080_CR26","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/gps.4102","volume":"29","author":"K Ito","year":"2014","unstructured":"Ito K, Shimano Y, Imabayashi E, Nakata Y, Omachi Y, Sato N, et al. Concordance between 99mTc-ECD SPECT and 18F-FDG PET interpretations in patients with cognitive disorders diagnosed according to NIA-AA criteria. Int J Geriatr Psychiatry. 2014;29(10):1079\u201386.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2080_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.arr.2016.02.003","volume":"30","author":"T Kato","year":"2016","unstructured":"Kato T, Inui Y, Nakamura A, Ito K. Brain fluorodeoxyglucose (FDG) PET in dementia. Ageing Res Rev. 2016;30:73\u201384.","journal-title":"Ageing Res Rev"},{"key":"2080_CR28","first-page":"1238","volume":"36","author":"S Minoshima","year":"1995","unstructured":"Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer\u2019s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238\u201348.","journal-title":"J Nucl Med"},{"key":"2080_CR29","first-page":"1450","volume":"45","author":"E Imabayashi","year":"2004","unstructured":"Imabayashi E, Matsuda H, Asada T, Ohnishi T, Sakamoto S, Nakano S, et al. Superiority of 3-dimensional stereotactic surface projection analysis over visual inspection in discrimination of patients with very early Alzheimer\u2019s disease from controls using brain perfusion SPECT. J Nucl Med. 2004;45:1450\u20137.","journal-title":"J Nucl Med"},{"key":"2080_CR30","first-page":"731","volume":"28","author":"H Matsuda","year":"2007","unstructured":"Matsuda H, Mizumura S, Nagao T, Ota T, Iizuka T, Nemoto K, et al. Automated discrimination between very early Alzheimer disease and controls using an easy Z-score imaging system for multicenter brain perfusion single-photon emission tomography. AJNR Am J Neuroradiol. 2007;28:731\u20136.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"4","key":"2080_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol"},{"key":"2080_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/ana.410420114","volume":"42","author":"S Minoshima","year":"1997","unstructured":"Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer\u2019s disease. Ann Neurol. 1997;42:85\u201394.","journal-title":"Ann Neurol"},{"key":"2080_CR33","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.2967\/jnumed.106.037218","volume":"48","author":"H Matsuda","year":"2007","unstructured":"Matsuda H. Role of neuroimaging in Alzheimer\u2019s disease, with emphasis on brain perfusion SPECT. J Nucl Med. 2007;48:1289\u2013300.","journal-title":"J Nucl Med"},{"key":"2080_CR34","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3233\/JAD-2011-110458","volume":"26","author":"LM Bloudek","year":"2011","unstructured":"Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer\u2019s disease. J Alzheimers Dis. 2011;26:627\u201345.","journal-title":"J Alzheimers Dis"},{"key":"2080_CR35","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s12149-018-1292-6","volume":"32","author":"V Valotassiou","year":"2018","unstructured":"Valotassiou V, Malamitsi J, Papatriantafyllou J, Dardiotis E, Tsougos I, Psimadas D, et al. SPECT and PET imaging in Alzheimer\u2019s disease. Ann Nucl Med. 2018;32:583\u201393.","journal-title":"Ann Nucl Med"},{"key":"2080_CR36","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s12149-013-0768-7","volume":"27","author":"K Ito","year":"2013","unstructured":"Ito K, Mori E, Fukuyama H, Ishii K, Washimi Y, Asada T, et al. Prediction of outcomes in MCI with 123I-IMP-CBF SPECT: a multicenter prospective cohort study. Ann Nucl Med. 2013;27:898\u2013906.","journal-title":"Ann Nucl Med"},{"issue":"3","key":"2080_CR37","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3233\/JAD-170395","volume":"60","author":"Y Inui","year":"2017","unstructured":"Inui Y, Ito K, Kato T, SEAD-J Study Group. Longer-term investigation of the value of 18F-FDG-PET and magnetic resonance imaging for predicting the conversion of mild cognitive impairment to Alzheimer\u2019s disease: a multicenter study. J Alzheimers Dis. 2017;60(3):877\u201387.","journal-title":"J Alzheimers Dis"},{"key":"2080_CR38","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1212\/WNL.0000000000009058","volume":"94","author":"D Ferreira","year":"2020","unstructured":"Ferreira D, Nordberg A, Westman E. Biological subtypes of Alzheimer disease: a systematic review and meta-analysis. Neurology. 2020;94:436\u201348.","journal-title":"Neurology"},{"key":"2080_CR39","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2967\/jnumed.117.206300","volume":"59","author":"A Drzezga","year":"2018","unstructured":"Drzezga A. The network degeneration hypothesis: spread of neurodegenerative patterns along neuronal brain networks. J Nucl Med. 2018;59:1645\u20138.","journal-title":"J Nucl Med"},{"key":"2080_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12020146","volume":"12","author":"K Herholz","year":"2022","unstructured":"Herholz K. Imaging clinical subtypes and associated brain networks in Alzheimer\u2019s disease. Brain Sci. 2022;12:146.","journal-title":"Brain Sci"},{"issue":"5","key":"2080_CR41","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s12149-025-02025-8","volume":"39","author":"J Lu","year":"2025","unstructured":"Lu J, Chen K, Lin H, Ju Z, Ge J, Lu J, et al. Phenotype-specific metabolic patterns in posterior cortical atrophy and early-onset typical Alzheimer\u2019s disease. Ann Nucl Med. 2025;39(5):506\u201317.","journal-title":"Ann Nucl Med"},{"key":"2080_CR42","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88\u2013100.","journal-title":"Neurology"},{"key":"2080_CR43","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1212\/WNL.53.2.413","volume":"53","author":"K Ishii","year":"1999","unstructured":"Ishii K, Yamaji S, Kitagaki H, Imamura T, Hirono N, Mori E. Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology. 1999;53:413\u20136.","journal-title":"Neurology"},{"key":"2080_CR44","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1212\/WNL.56.5.643","volume":"56","author":"K Lobotesis","year":"2001","unstructured":"Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology. 2001;56:643\u20139.","journal-title":"Neurology"},{"key":"2080_CR45","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00406-013-0426-z","volume":"263","author":"JM Yeo","year":"2013","unstructured":"Yeo JM, Lim X, Khan Z, Pal S. Systematic review of the diagnostic utility of SPECT imaging in dementia. Eur Arch Psychiatry Clin Neurosci. 2013;263:539\u201352.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"3","key":"2080_CR46","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s11604-023-01501-3","volume":"42","author":"T Nakata","year":"2024","unstructured":"Nakata T, Shimada K, Iba A, Oda H, Terashima A, Koide Y, et al. Differential diagnosis of MCI with Lewy bodies and MCI due to Alzheimer\u2019s disease by visual assessment of occipital hypoperfusion on SPECT images. Jpn J Radiol. 2024;42(3):308\u201318.","journal-title":"Jpn J Radiol"},{"issue":"3","key":"2080_CR47","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/ana.1133","volume":"50","author":"S Minoshima","year":"2001","unstructured":"Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer\u2019s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50(3):358\u201365.","journal-title":"Ann Neurol"},{"key":"2080_CR48","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s12149-014-0873-2","volume":"28","author":"Y Inui","year":"2014","unstructured":"Inui Y, Toyama H, Manabe Y, Sarai M, Iwata N. Comparison of 123I-MIBG myocardial scintigraphy, brain perfusion SPECT, and voxel-based MRI morphometry for distinguishing between dementia with Lewy bodies and Alzheimer\u2019s disease. Ann Nucl Med. 2014;28:796\u2013804.","journal-title":"Ann Nucl Med"},{"key":"2080_CR49","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1212\/WNL.0000000000000734","volume":"83","author":"J Graff-Radford","year":"2014","unstructured":"Graff-Radford J, Murray ME, Lowe VJ, Boeve BF, Ferman TJ, Przybelski SA, et al. Dementia with Lewy bodies: basis of cingulate island sign. Neurology. 2014;83:801\u20139.","journal-title":"Neurology"},{"key":"2080_CR50","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","volume":"94","author":"IG McKeith","year":"2020","unstructured":"McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94:743\u201355.","journal-title":"Neurology"},{"key":"2080_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15263-2","volume":"7","author":"T Iizuka","year":"2017","unstructured":"Iizuka T, Iizuka R, Kameyama M. Cingulate island sign temporally changes in dementia with Lewy bodies. Sci Rep. 2017;7:14745.","journal-title":"Sci Rep"},{"key":"2080_CR52","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s12149-017-1181-4","volume":"31","author":"E Imabayashi","year":"2017","unstructured":"Imabayashi E, Soma T, Sone D, Tsukamoto T, Kimura Y, Sato N, et al. Validation of the cingulate island sign with optimized ratios for discriminating dementia with Lewy bodies from Alzheimer\u2019s disease using brain perfusion SPECT. Ann Nucl Med. 2017;31:536\u201343.","journal-title":"Ann Nucl Med"},{"issue":"10","key":"2080_CR53","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1007\/s11604-024-01604-5","volume":"42","author":"G Honda","year":"2024","unstructured":"Honda G, Nagamachi S, Takahashi M, Higuma Y, Tani T, Hida K, et al. The development of new method to differentiate between dementia with Lewy bodies and Alzheimer\u2019s disease by cerebral perfusion SPECT-comparison to CIScore. Jpn J Radiol. 2024;42(10):1206\u201312.","journal-title":"Jpn J Radiol"},{"key":"2080_CR54","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456\u201377.","journal-title":"Brain"},{"key":"2080_CR55","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006\u201314.","journal-title":"Neurology"},{"key":"2080_CR56","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S1474-4422(21)00341-0","volume":"21","author":"BF Boeve","year":"2022","unstructured":"Boeve BF, Boxer AL, Kumfor F, Pijnenburg Y, Rohrer JD. Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. Lancet Neurol. 2022;21:258\u201372.","journal-title":"Lancet Neurol"},{"key":"2080_CR57","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/1531-8249(200001)47:1<36::AID-ANA8>3.0.CO;2-L","volume":"47","author":"CJ Mummery","year":"2000","unstructured":"Mummery CJ, Patterson K, Price CJ, Ashburner J, Frackowiak RS, Hodges JR. A voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory. Ann Neurol. 2000;47:36\u201345.","journal-title":"Ann Neurol"},{"key":"2080_CR58","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1093\/brain\/awg240","volume":"126","author":"PJ Nestor","year":"2003","unstructured":"Nestor PJ, Graham NL, Fryer TD, Williams GB, Patterson K, Hodges JR. Progressive non-fluent aphasia is associated with hypometabolism centred on the left anterior insula. Brain. 2003;126:2406\u201318.","journal-title":"Brain"},{"key":"2080_CR59","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/bs.pmbts.2019.05.009","volume":"165","author":"JL Whitwell","year":"2019","unstructured":"Whitwell JL. FTD spectrum: neuroimaging across the FTD spectrum. Prog Mol Biol Transl Sci. 2019;165:187\u2013223.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"6","key":"2080_CR60","doi-asserted-by":"publisher","first-page":"fcad296","DOI":"10.1093\/braincomms\/fcad296","volume":"5","author":"I Aiba","year":"2023","unstructured":"Aiba I, Hayashi Y, Shimohata T, Yoshida M, Saito Y, Wakabayashi K, et al. Clinical course of pathologically confirmed corticobasal degeneration and corticobasal syndrome. Brain Commun. 2023;5(6):fcad296.","journal-title":"Brain Commun."},{"key":"2080_CR61","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/jnnp-2021-328586","volume":"93","author":"S Koga","year":"2022","unstructured":"Koga S, Josephs KA, Aiba I, Yoshida M, Dickson DW. Neuropathology and emerging biomarkers in corticobasal syndrome. J Neurol Neurosurg Psychiatry. 2022;93:919\u201329.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"2080_CR62","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00234-024-03432-w","volume":"66","author":"K Sakurai","year":"2024","unstructured":"Sakurai K, Tokumaru AM, Yoshida M, Saito Y, Wakabayashi K, Komori T, et al. Conventional magnetic resonance imaging key features for distinguishing pathologically confirmed corticobasal degeneration from its mimics: a retrospective analysis of the J-VAC study. Neuroradiology. 2024;66(11):1917\u201329.","journal-title":"Neuroradiology"},{"issue":"1","key":"2080_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39227-x","volume":"13","author":"M Kurihara","year":"2023","unstructured":"Kurihara M, Ishibashi K, Matsubara T, Hatano K, Ihara R, Higashihara M, et al. High sensitivity of asymmetric 18F-THK5351 PET abnormality in patients with corticobasal syndrome. Sci Rep. 2023;13(1):12147.","journal-title":"Sci Rep"},{"key":"2080_CR64","doi-asserted-by":"publisher","first-page":"e1121","DOI":"10.1212\/WNL.0000000000007038","volume":"92","author":"M Pardini","year":"2019","unstructured":"Pardini M, Huey ED, Spina S, Kreisl WC, Morbelli S, Wassermann EM, et al. FDG-PET patterns associated with underlying pathology in corticobasal syndrome. Neurology. 2019;92:e1121\u201335.","journal-title":"Neurology"},{"key":"2080_CR65","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853\u201364.","journal-title":"Mov Disord"},{"key":"2080_CR66","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/mds.27872","volume":"35","author":"G Respondek","year":"2020","unstructured":"Respondek G, Grimm MJ, Piot I, Arzberger T, Compta Y, Englund E, et al. Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. Mov Disord. 2020;35:171\u20136.","journal-title":"Mov Disord"},{"key":"2080_CR67","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1212\/WNL.0b013e318292a2d2","volume":"80","author":"LA Massey","year":"2013","unstructured":"Massey LA, Jager HR, Paviour DC, O\u2019Sullivan SS, Lees AJ, Williams D, et al. The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology. 2013;80:1856\u201361.","journal-title":"Neurology"},{"key":"2080_CR68","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00234-017-1812-4","volume":"59","author":"K Sakurai","year":"2017","unstructured":"Sakurai K, Tokumaru AM, Shimoji K, Nakagawa M, Noda M, Shibata E, et al. Beyond the midbrain atrophy: wide spectrum of structural MRI finding in cases of pathologically proven progressive supranuclear palsy. Neuroradiology. 2017;59:431\u201343.","journal-title":"Neuroradiology"},{"key":"2080_CR69","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/mds.28364","volume":"36","author":"A Quattrone","year":"2021","unstructured":"Quattrone A, Nicoletti G, Messina D, Fera F, Berardelli A, Morgante L, et al. A new MRI measure to early differentiate progressive supranuclear palsy from de novo Parkinson\u2019s disease in clinical practice: an international study. Mov Disord. 2021;36:681\u20139.","journal-title":"Mov Disord"},{"key":"2080_CR70","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.9588","volume":"5","author":"I Ill\u00e1n-Gala","year":"2022","unstructured":"Ill\u00e1n-Gala I, Lleo A, Carmona-Iragui M, Sala I, Fern\u00e1ndez-Lebrero A, Navalpotro-G\u00f3mez I, et al. Diagnostic accuracy of magnetic resonance imaging measures of brain atrophy across the spectrum of progressive supranuclear palsy and corticobasal degeneration. JAMA Netw Open. 2022;5:e229588.","journal-title":"JAMA Netw Open"},{"key":"2080_CR71","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/mds.27038","volume":"32","author":"JL Whitwell","year":"2017","unstructured":"Whitwell JL, H\u00f6glinger GU, Antonini A, Bordelon Y, Boxer AL, Colosimo C, et al. Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be? Mov Disord. 2017;32:955\u201371.","journal-title":"Mov Disord"},{"key":"2080_CR72","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-510X(02)00102-8","volume":"199","author":"K Hosaka","year":"2002","unstructured":"Hosaka K, Ishii K, Sakamoto S, Mori T, Sasaki M, Hirono N, et al. Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration. J Neurol Sci. 2002;199:67\u201371.","journal-title":"J Neurol Sci"},{"key":"2080_CR73","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/mds.29005","volume":"37","author":"GK Wenning","year":"2022","unstructured":"Wenning GK, Stankovic I, Vignatelli L, Fanciulli A, Calandra-Buonaura G, Seppi K, et al. The Movement Disorder Society criteria for the diagnosis of multiple system atrophy. Mov Disord. 2022;37:1131\u201348.","journal-title":"Mov Disord"},{"issue":"8","key":"2080_CR74","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.3233\/JPD-223444","volume":"12","author":"Y Cui","year":"2022","unstructured":"Cui Y, Cao S, Li F, Feng T. Prevalence and clinical characteristics of dementia and cognitive impairment in multiple system atrophy: a systematic review and meta-analysis. J Parkinsons Dis. 2022;12(8):2383\u201395.","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"2080_CR75","first-page":"61","volume":"113","author":"J Levin","year":"2016","unstructured":"Levin J, Kurz A, Arzberger T, Giese A, H\u00f6glinger GU. The differential diagnosis and treatment of atypical parkinsonism. Dtsch Arztebl Int. 2016;113(5):61\u20139.","journal-title":"Dtsch Arztebl Int"},{"key":"2080_CR76","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1474-4422(03)00662-8","volume":"3","author":"GK Wenning","year":"2004","unstructured":"Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol. 2004;3:93\u2013103.","journal-title":"Lancet Neurol"},{"key":"2080_CR77","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrneurol.2017.26","volume":"13","author":"F Krismer","year":"2017","unstructured":"Krismer F, Wenning GK. Multiple system atrophy: insights into a rare and debilitating movement disorder. Nat Rev Neurol. 2017;13:232\u201343.","journal-title":"Nat Rev Neurol"},{"key":"2080_CR78","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1212\/WNL.54.3.697","volume":"54","author":"A Schrag","year":"2000","unstructured":"Schrag A, Good CD, Miszkiel K, Morris HR, Mathias CJ, Lees AJ, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology. 2000;54:697\u2013702.","journal-title":"Neurology"},{"key":"2080_CR79","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/mdc3.13550","volume":"9","author":"AK Naidoo","year":"2022","unstructured":"Naidoo AK, Bhatt M, Bhattacharya K. The, \u201chot cross bun sign\u201d in spinocerebellar ataxia types 2 and 7\u2013-case reports and review of literature. Mov Disord Clin Pract. 2022;9:1105\u201313.","journal-title":"Mov Disord Clin Pract"},{"key":"2080_CR80","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/mdc3.13596","volume":"9","author":"S Prasad","year":"2022","unstructured":"Prasad S, Bhatt M, Bhattacharya K, Saini J, Pal PK. The hot cross bun sign: a journey across etiologies. Mov Disord Clin Pract. 2022;9:1018\u201320.","journal-title":"Mov Disord Clin Pract"},{"issue":"3","key":"2080_CR81","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.neuroimage.2005.03.012","volume":"26","author":"T Eckert","year":"2005","unstructured":"Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005;26(3):912\u201321.","journal-title":"Neuroimage"},{"issue":"2","key":"2080_CR82","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1474-4422(10)70002-8","volume":"9","author":"CC Tang","year":"2010","unstructured":"Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 2010;9(2):149\u201358.","journal-title":"Lancet Neurol"},{"key":"2080_CR83","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1136\/jnnp.2006.110122","volume":"78","author":"Z Walker","year":"2007","unstructured":"Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;78:1176\u201381.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2080_CR84","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","volume":"6","author":"I McKeith","year":"2007","unstructured":"McKeith I, O\u2019Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305\u201313.","journal-title":"Lancet Neurol"},{"issue":"7","key":"2080_CR85","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1007\/s00259-023-06154-y","volume":"50","author":"M Jreige","year":"2023","unstructured":"Jreige M, Kurian GK, Perriraz J, Potheegadoo J, Bernasconi F, Stampacchia S, et al. The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review. Eur J Nucl Med Mol Imaging. 2023;50(7):1988\u20132035.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2080_CR86","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1093\/brain\/aws211","volume":"135","author":"SJ Colloby","year":"2012","unstructured":"Colloby SJ, McParland S, O\u2019Brien JT, Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer\u2019s disease and Lewy body dementias. Brain. 2012;135:2798\u2013808.","journal-title":"Brain"},{"key":"2080_CR87","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268669","author":"C Shang","year":"2026","unstructured":"Shang C, Nagao R, Riku Y, Ichihara T, Inui Y, Ishiguro M, et al. Serotonin transporter distribution in the brainstem of multiple-system atrophy\u2013parkinsonian type: insights from pathology and 123I-FP-CIT SPECT findings. J Nucl Med. 2026. https:\/\/doi.org\/10.2967\/jnumed.124.268669.","journal-title":"J Nucl Med"},{"issue":"6","key":"2080_CR88","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00401-005-0995-7","volume":"109","author":"S Orimo","year":"2005","unstructured":"Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T, et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol. 2005;109(6):583\u20138.","journal-title":"Acta Neuropathol"},{"issue":"16","key":"2080_CR89","doi-asserted-by":"publisher","first-page":"e1648","DOI":"10.1212\/WNL.0000000000200110","volume":"98","author":"T Matsubara","year":"2022","unstructured":"Matsubara T, Kameyama M, Tanaka N, Sengoku R, Orita M, Furuta K, et al. Autopsy validation of the diagnostic accuracy of 123I-metaiodobenzylguanidine myocardial scintigraphy for Lewy body disease. Neurology. 2022;98(16):e1648\u201359.","journal-title":"Neurology"},{"key":"2080_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120540","volume":"10","author":"M Yoshita","year":"2015","unstructured":"Yoshita M, Arai H, Arai H, Arai T, Asada T, Fujishiro H, et al. Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. PLoS ONE. 2015;10:e0120540.","journal-title":"PLoS ONE"},{"key":"2080_CR91","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/jnnp-2017-317398","volume":"89","author":"J Komatsu","year":"2018","unstructured":"Komatsu J, Samuraki M, Nakajima K, Arai H, Arai H, Arai T, et al. 123I-MIBG myocardial scintigraphy for the diagnosis of DLB: a multicentre 3-year follow-up study. J Neurol Neurosurg Psychiatry. 2018;89:1167\u201373.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"2080_CR92","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00234-019-02247-4","volume":"61","author":"K Sakurai","year":"2019","unstructured":"Sakurai K, Tokumaru AM, Ikeda T, Morimoto S, Inui S, Sumida K, et al. Characteristic asymmetric limbic and anterior temporal atrophy in demented patients with pathologically confirmed argyrophilic grain disease. Neuroradiology. 2019;61(11):1239\u20131249.","journal-title":"Neuroradiology"},{"issue":"4","key":"2080_CR93","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.3233\/JAD-210638","volume":"84","author":"K Sakurai","year":"2021","unstructured":"Sakurai K, Iwase T, Kaneda D, Uchida Y, Inui S, Morimoto S, et al. Sloping shoulders sign: a practical radiological sign for the differentiation of Alzheimer\u2019s disease and argyrophilic grain disease. J Alzheimers Dis. 2021;84(4):1719\u20131727.","journal-title":"J Alzheimers Dis."},{"key":"2080_CR94","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1007\/s00259-019-04379-4","volume":"46","author":"A Chiaravalloti","year":"2019","unstructured":"Chiaravalloti A, Barbagallo G, Martorana A, Koch G, Bonanno L, Ricci M, et al. Brain metabolic patterns in patients with suspected non-Alzheimer\u2019s pathophysiology (SNAP) and Alzheimer\u2019s disease (AD): is FDG a specific biomarker in these patients? Eur J Nucl Med Mol Imaging. 2019;46:1796\u2013805.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2080_CR95","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(11)70289-7","volume":"11","author":"SJ Crutch","year":"2012","unstructured":"Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Fox NC. Posterior cortical atrophy. Lancet Neurol. 2012;11:170\u20138.","journal-title":"Lancet Neurol"},{"key":"2080_CR96","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1097\/RLU.0000000000001602","volume":"42","author":"N Miyazawa","year":"2017","unstructured":"Miyazawa N, Shinmyo T, Mitsui Y, Kaneko J, Hara A, Tanaka K, et al. Creutzfeldt-Jakob disease mimicking Alzheimer\u2019s disease and dementia with Lewy bodies: findings of FDG PET with 3-dimensional stereotactic surface projection. Clin Nucl Med. 2017;42:e247-248.","journal-title":"Clin Nucl Med"},{"key":"2080_CR97","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1468-1331.2011.03570.x","volume":"19","author":"EJ Kim","year":"2012","unstructured":"Kim EJ, Cho SS, Jeong BH, Kim YE, Seo SW, Kim GM, et al. Glucose metabolism in sporadic Creutzfeldt-Jakob disease: a statistical parametric mapping analysis of (18)F-FDG PET. Eur J Neurol. 2012;19:488\u201393.","journal-title":"Eur J Neurol"},{"key":"2080_CR98","first-page":"548","volume":"42","author":"K Ishii","year":"2001","unstructured":"Ishii K, Willoch F, Minoshima S, Drzezga A, Ficaro EP, Cross DJ, et al. Statistical brain mapping of 18F-FDG PET in Alzheimer\u2019s disease: validation of anatomic standardization for atrophied brains. J Nucl Med. 2001;42:548\u201357.","journal-title":"J Nucl Med"},{"key":"2080_CR99","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321:1286\u201394.","journal-title":"JAMA"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-02080-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-026-02080-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-02080-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:02:48Z","timestamp":1791007368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-026-02080-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":99,"alternative-id":["2080"],"URL":"https:\/\/doi.org\/10.1007\/s11604-026-02080-9","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"9 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All imaging data presented in this review were obtained from previous studies conducted in accordance with the ethical standards of the respective institutional review boards. Ethical approval was obtained at each participating institution.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all patients in accordance with the requirements of each study. Where applicable, consent was obtained either through written informed consent or through an opt-out procedure for the retrospective use of nuclear medicine imaging data.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}